BNP Paribas Financial Markets Sells 406,410 Shares of Qiagen (NYSE:QGEN)

BNP Paribas Financial Markets reduced its holdings in Qiagen (NYSE:QGEN) by 16.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,112,202 shares of the company’s stock after selling 406,410 shares during the quarter. BNP Paribas Financial Markets owned about 0.93% of Qiagen worth $96,253,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. TD Asset Management Inc bought a new stake in Qiagen in the second quarter valued at $2,103,000. Raymond James & Associates boosted its stake in shares of Qiagen by 12.7% during the 2nd quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock valued at $22,289,000 after purchasing an additional 61,008 shares in the last quarter. Jennison Associates LLC increased its position in shares of Qiagen by 5.0% during the third quarter. Jennison Associates LLC now owns 1,426,392 shares of the company’s stock valued at $65,001,000 after buying an additional 68,415 shares during the period. Barings LLC purchased a new position in shares of Qiagen during the second quarter valued at about $12,463,000. Finally, Sei Investments Co. raised its stake in Qiagen by 19.7% in the second quarter. Sei Investments Co. now owns 1,696,319 shares of the company’s stock worth $69,702,000 after buying an additional 278,930 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $43.26 on Wednesday. The business has a fifty day moving average price of $43.37 and a 200-day moving average price of $43.73. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The company has a market capitalization of $9.87 billion, a PE ratio of 110.92, a PEG ratio of 3.35 and a beta of 0.41. Qiagen has a 1-year low of $39.03 and a 1-year high of $47.44.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Robert W. Baird upped their target price on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a report on Thursday, October 17th. Finally, Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $50.88.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.